CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.15B, above the global median of $1.15B
- PositionOperating margin is -13930.7%, lower than 95% of its Biotechnology peers (median -23.8%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.15BUSDvs all stocks (USD)
Revenue (TTM)
79.76MUSDvs all stocks (USD)
Profit Margin
-151.12%vs Biotechnology peers
Beta
1.21xvs all stocks
52-Week Change
43.15%vs all stocks
Market Capitalization
1.15BUSDvs all stocks (USD)
Enterprise Value
1.17BUSDvs all stocks (USD)
Forward P/E
-9.10xvs Biotechnology peers
Price to Sales (TTM)
14.44xvs Biotechnology peers
Enterprise to Revenue
14.64xvs Biotechnology peers
Enterprise to EBITDA
-12.60xvs Biotechnology peers
Gross Margin
32.42%vs Biotechnology peers
Profit Margin
-151.12%vs Biotechnology peers
Return on Assets (TTM)
-28.06%vs Biotechnology peers
Revenue (TTM)
79.76MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.9850USDUpdated Jul 19, 2026Quarterly Revenue Growth
-84.80%vs Biotechnology peers
Gross Profit (TTM)
76.09MUSDvs all stocks (USD)
EBITDA (TTM)
-92.72MUSDvs all stocks (USD)
Net Income (TTM)
-120.53MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-84.79%vs Biotechnology peers
Operating Cash Flow (TTM)
8.28MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
45.02MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
81.39MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
4.84MUSDFY2025 · Dec 31, 2025Gross Profit
76.55MUSDFY2025 · Dec 31, 2025Operating Income
-105.97MUSDvs all stocks (USD)
Pre-tax Income
-114.20MUSDFY2025 · Dec 31, 2025Net Income
-114.20MUSDFY2025 · Dec 31, 2025EBIT
-102.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.54MUSDFY2025 · Dec 31, 2025Research & Development
129.62MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
52.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.82MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
12.20MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.42USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.42USDFY2025 · Dec 31, 2025Basic Shares Outstanding
80.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
80.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-114.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-49.70MUSDFY2025 · Dec 31, 2025Free Cash Flow
-53.39MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
68.19MUSDFY2025 · Dec 31, 2025Interest Paid
11.04MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-114.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
12.61MUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
6.89MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.27MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-12.31MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
42.48MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.70MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-410.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.70MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-29.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.03MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
12.02MUSDFY2025 · Dec 31, 2025Shares Outstanding
81.45MSharesUpdated Jul 19, 2026Float Shares
52.29MSharesUpdated Jul 19, 2026Shares Short
4.72MSharesUpdated Jul 19, 2026Short Ratio
4.39daysvs all stocks
Short % of Shares Outstanding
7.21%vs all stocks
% Held by Insiders
17.12%vs all stocks
% Held by Institutions
61.57%vs all stocks
Total Cash (MRQ)
71.54MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7730USDUpdated Jul 19, 2026Total Debt (MRQ)
87.53MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.5460xvs Biotechnology peers
Book Value per Share (MRQ)
-0.7140USDUpdated Jul 19, 2026Total Assets
244.43MUSDvs all stocks (USD)
Total Current Assets
91.76MUSDFY2025 · Dec 31, 2025Total Liabilities
250.22MUSDFY2025 · Dec 31, 2025Total Non-current Assets
152.67MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
127.67MUSDFY2025 · Dec 31, 2025Total Current Liabilities
122.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
65.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.00MUSDFY2025 · Dec 31, 2025Inventory
0.00USDFY2025 · Dec 31, 2025Accounts Payable
10.07MUSDFY2025 · Dec 31, 2025Short-term Debt
27.54MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.78MUSDFY2025 · Dec 31, 2025Other Current Liabilities
50.28MUSDFY2025 · Dec 31, 2025Long-term Debt
61.15MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-816.22MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-5.79MUSDvs all stocks (USD)
52-Week Low
6.62USDUpdated Jul 19, 202652-Week High
15.35USDUpdated Jul 19, 202652-Week Change
43.15%vs all stocks
Beta
1.21xvs all stocks
50-Day MA
10.87USDUpdated Jul 19, 2026200-Day MA
8.89USDUpdated Jul 19, 2026Avg 10-Day Volume
1.00MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.11MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.49USDUpdated Jul 19, 2026Other Income / Expense
2.15MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -13930.7%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -139.307Industry median: -0.24Industry P5: -32.91Peers compared: 197
Current ratio is 0.55×, lower than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 0.55Industry median: 5.50Industry P5: 0.97Peers compared: 197
Financial Health
Consistent revenue growth patternNotable
Growth Consistency Score: 0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.15B, above the global median of $1.15BNotable
Market cap (USD): 1,152,062,379Global Median: 1,146,734,693.424
Levered free cash flow is $45.02M, above the global median of $16.24MNotable
Levered free cash flow (USD): 45,015,624Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eton Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
BioGaia AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SSY Group Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Eastern Shenghong Co., Ltd.
1 interpretationWithin or Near the Altman Distress Zone
Naturgy Energy Group, S.A.
1 interpretationWithin or Near the Altman Distress Zone
Delivery Hero SE
1 interpretationWithin or Near the Altman Distress Zone